Taking pravastatin for 3 months didn't raise or lower average blood sugar or long-term glucose control in kidney transplant patients without diabetes.
Scientific Claim
Pravastatin at 40 mg/day for 12 weeks does not significantly alter fasting plasma glucose or HbA1c levels in non-diabetic kidney transplant recipients compared to placebo.
Original Statement
“Mean fasting P-glucose 5.5 mmol/l... after pravastatin treatment and 5.4 mmol/l... after placebo treatment, with no significant difference between the two groups (95% CI −0.33 to 0.33, P = 1.00). Mean HbA1c was 36.9 mmol/mol... and 36.3 mmol/mol... with a non-significant difference of −0.5 mmol/mol (95% CI −2.4 to 1.3, P = 0.53).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The RCT design supports causal inference, but small sample size and wide confidence intervals warrant probabilistic language. The authors correctly reported non-significance without claiming absence of effect.
More Accurate Statement
“Pravastatin at 40 mg/day for 12 weeks may not significantly alter fasting plasma glucose or HbA1c levels in non-diabetic kidney transplant recipients compared to placebo.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether pravastatin consistently has no effect on HbA1c and fasting glucose across diverse kidney transplant populations.
Whether pravastatin consistently has no effect on HbA1c and fasting glucose across diverse kidney transplant populations.
What This Would Prove
Whether pravastatin consistently has no effect on HbA1c and fasting glucose across diverse kidney transplant populations.
Ideal Study Design
Meta-analysis of all RCTs comparing pravastatin (40 mg/day) to placebo or no treatment in non-diabetic kidney transplant recipients, with pooled mean differences in HbA1c and fasting glucose over ≥12 weeks, stratified by time since transplant and immunosuppressive regimen.
Limitation: Cannot assess long-term PTDM risk or effects in patients with pre-existing insulin resistance.
Randomized Controlled TrialLevel 1bIn EvidenceWhether pravastatin causes no meaningful change in HbA1c or fasting glucose in this population with adequate power.
Whether pravastatin causes no meaningful change in HbA1c or fasting glucose in this population with adequate power.
What This Would Prove
Whether pravastatin causes no meaningful change in HbA1c or fasting glucose in this population with adequate power.
Ideal Study Design
Double-blind RCT with 150+ non-diabetic kidney transplant recipients, randomized to pravastatin 40 mg/day vs. placebo for 24 weeks, with HbA1c and fasting glucose measured at baseline, 12, and 24 weeks as primary endpoints.
Limitation: Limited to short-term metabolic effects; cannot assess impact on PTDM incidence.
Prospective Cohort StudyLevel 2bWhether long-term pravastatin use is associated with stable HbA1c trajectories in real-world transplant care.
Whether long-term pravastatin use is associated with stable HbA1c trajectories in real-world transplant care.
What This Would Prove
Whether long-term pravastatin use is associated with stable HbA1c trajectories in real-world transplant care.
Ideal Study Design
Prospective cohort of 300+ non-diabetic kidney transplant recipients followed for 5 years, comparing HbA1c trends in those prescribed pravastatin vs. other statins or no statin, adjusting for age, BMI, and immunosuppression.
Limitation: Cannot prove causation due to confounding by prescribing patterns and adherence.
Evidence from Studies
Supporting (1)
This study gave 11 non-diabetic kidney transplant patients pravastatin for 12 weeks and found their blood sugar and HbA1c levels didn’t change compared to when they took a placebo—so pravastatin doesn’t mess with their blood sugar at this dose.